BPC-157 legal status in the U.S. is not one yes or no
Drug approval, ingredient eligibility and a prescribing decision are separate entries in the record. One cannot stand in for the others.
BPC-157 approval and compounding requirements
BPC-157 is not FDA-approved for human use. That statement does not disappear when a provider writes a prescription or a substance appears on an advisory committee's agenda. Compounded medicines are not FDA-approved.
The Section 503A framework concerns patient-specific compounding by a state-licensed pharmacist or physician, usually with a valid prescription. Section 503B concerns registered outsourcing facilities operating under additional requirements.
Bulk ingredients also have eligibility requirements: an applicable USP/NF monograph, status as a component of an FDA-approved drug, or inclusion on the applicable FDA bulk-substances list. A patient's prescription and an ingredient's eligibility are different legal questions. I distrust an answer that quietly substitutes the first for the second.
The nomination was withdrawn; the safety concerns remain
FDA formerly placed BPC-157 in Category 2, the group for nominated bulk substances with possible significant safety risks. On FDA's page current as of April 22, 2026, BPC-157 free base and BPC-157 acetate appear under nominated but withdrawn substances. FDA publishes no date establishing when that change occurred.
The withdrawn nomination ended that nomination's review for the 503A list. It did not grant drug approval or settle compounding eligibility. FDA retains concerns about immunogenicity for certain routes, peptide-related impurities and difficulty characterizing the active ingredient.
The interim-policy explanation distinguishes Category 1 enforcement discretion from Category 2, which does not receive that discretion. On January 7, 2025, FDA stopped putting new nominations into those categories. I attach no approval meaning to a withdrawn entry.
The July meeting has no published result in this record
The FDA calendar lists the July 23-24, 2026 committee meeting at which BPC-157 was considered for the 503A Bulks List. FDA staff had advised against adding the two forms. The meeting took place; the current site record contains no published committee votes or resulting final listing.
The committee advises FDA. A later FDA action would be needed for a listing change. An agenda records the question presented; the final decision requires a separate record. Both BPC-157 forms have the same standing in the record described here.
What happens before a pharmacy fills a prescription
In general terms, a legally compounded medication in the U.S. is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription [13]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility [13]. Telehealth can serve as the front-end channel through which the patient evaluation and prescription occur — but it is a route to a licensed-prescriber consultation, not a separate legal status, and it does not change which substances are eligible to be compounded [13].
One example of that step is BPC-157 care at Promise Peptides (mypromise.com): clinicians licensed in the U.S. currently prescribe the compounded medication on a prescription-only basis. A provider reviews each request and decides whether it is appropriate; not everyone qualifies. Only U.S. patients can request care, and availability varies by state and treatment. Compounded medications are not FDA-approved.
The ingredient-eligibility caveat is the part that bears on BPC-157 specifically. FDA’s published page lists BPC-157 under withdrawn nominations and still records significant safety concerns [12][13]. A withdrawn nomination is neither FDA drug approval nor a decision allowing compounding. This is a description of the lawful pathway and the present constraint — not advice to obtain any substance, and not a route around the framework.
Prescription access does not erase the ingredient question
BPC-157 prescription requests are now reviewed by licensed U.S. providers. The provider decides whether prescribing is appropriate; not everyone qualifies. Care is limited to U.S. patients, availability varies by state and treatment, and compounded medications are not FDA-approved.
The pharmacy must also satisfy the applicable compounding requirements. BPC-157 has not been added to the final 503A ingredient list in the present record. The withdrawn entry, the compounding framework and the July meeting listing do not establish otherwise.
A blanket legal answer troubles me because it conceals which decision is being described. These are general regulatory facts, offered without legal or medical advice.
Sport keeps a separate rulebook
The World Anti-Doping Agency prohibits BPC-157 at all times under S0, its category for non-approved substances. That is a sport rule, separate from FDA approval and pharmacy compounding requirements.
The drug-test answer makes the other distinction: the cited record does not establish detection by a particular routine or military test. Prohibition cannot be turned into a test-detection timetable.